Dr Rishabh Jain/X
Oct 17, 2026, 16:17
Rishabh Jain: Could Rusfertide Transform Polycythemia Vera Management?
Rishabh Jain, Medical Oncologist at AIIMS Delhi, shared a post on X:
“VERIFY Phase III | JCO 2026
Could rusfertide transform polycythemia vera management?
293 patients | Rusfertide vs placebo and SOC
- Clinical response: 77% vs 33% (P<0.0001)
- Phlebotomy-free: 73% vs 22%
- Sustained Hct <45%: 63% vs 14%
Fatigue and symptom scores improved.
Injection-site reactions and anemia; thrombosis reduction remains unproven.
Verdict: First-in-class hepcidin mimetic delivers a major advance in hematocrit control and phlebotomy reduction.
Longer-term clinical outcomes are needed.”
More posts featuring Rishabh Jain on Hemostasis Today.
-
Oct 17, 2026, 16:16Fabrice Cognasse: Advancing Transfusion Medicine Through International Collaboration
-
Oct 17, 2026, 16:10Abdul Muqtadir Abbasi: PNH – How to Interpret Flow Cytometry
-
Oct 17, 2026, 16:10Lakshmi Kattamuri: Contemporary Evidence on Antithrombotic Therapy in AF and Chronic Coronary Disease
-
Oct 17, 2026, 16:05Gregg W. Stone: Short-Term DOACs Show Advantage Over DAPT Post-LAAO
-
Oct 17, 2026, 15:58Cristine Magallanes: Caring Beyond Hospitality – Accor Hosts Community Platelet Donation Drive
-
Oct 17, 2026, 15:57Isaac James: Zoster Vaccine Response in MPN Patients on JAK Inhibitors
-
Oct 17, 2026, 15:51Mohammad Reza Moghaddasnejad: A New Chapter in Cancer Research – Exploring the Role of Platelets in Cancer Metastasis
-
Oct 17, 2026, 15:44James P. Crowley: Drs. Blumberg and Heal Win SABM Sazama Award for Transfusion Research
-
Oct 17, 2026, 15:41X. Long Zheng։ ADAMTS13 and VWF in COVID-19-Associated Coagulopathy